209 related articles for article (PubMed ID: 30596709)
1. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model.
Zhao Y; Guo LL; Fang B; Liu B
PLoS One; 2018; 13(12):e0209177. PubMed ID: 30596709
[TBL] [Abstract][Full Text] [Related]
2.
Guo LL; Gao RY; Wang LH; Lin SJ; Fang BH; Zhao YD
Front Vet Sci; 2021; 8():715887. PubMed ID: 34869712
[TBL] [Abstract][Full Text] [Related]
3. PK/PD modeling of Ceftiofur Sodium against Haemophilus parasuis infection in pigs.
Li XD; Chi SQ; Wu LY; Liu C; Sun T; Hong J; Chen X; Chen XG; Wang GS; Yu DJ
BMC Vet Res; 2019 Aug; 15(1):272. PubMed ID: 31370843
[TBL] [Abstract][Full Text] [Related]
4. Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets.
Zhou YF; Bu MX; Liu P; Sun J; Liu YH; Liao XP
BMC Vet Res; 2020 Mar; 16(1):81. PubMed ID: 32138735
[TBL] [Abstract][Full Text] [Related]
5. Integration of pharmacokinetic-pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs.
Zhang L; Li Y; Wang Y; Sajid A; Ahmed S; Li X
J Vet Pharmacol Ther; 2018 Oct; 41(5):706-718. PubMed ID: 29696661
[TBL] [Abstract][Full Text] [Related]
6. In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.
Sun J; Xiao X; Huang RJ; Yang T; Chen Y; Fang X; Huang T; Zhou YF; Liu YH
BMC Vet Res; 2015 Dec; 11():293. PubMed ID: 26626889
[TBL] [Abstract][Full Text] [Related]
7. PK/PD modelling of enrofloxacin against Glaesserella parasuis infection in pigs.
Yang B; Li XD; Chen X; Hong J; Liu C; Zheng JP; Ou ZY; Yu DJ
J Vet Pharmacol Ther; 2022 May; 45(3):291-300. PubMed ID: 35348230
[TBL] [Abstract][Full Text] [Related]
8. A novel experimental intraperitoneal infection model for Haemophilus parasuis in neutropenic guinea pigs.
Zhao YD; Liu BT; Guo LL; Shan H; Fang BH
J Pharmacol Toxicol Methods; 2019; 95():27-35. PubMed ID: 30476621
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of tilmicosin in healthy pigs and in pigs experimentally infected with
Zhang L; Zhao L; Liu Y; Liu J; Li X
J Vet Sci; 2017 Dec; 18(4):431-437. PubMed ID: 28385011
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against
Zhou Q; Zhang G; Wang Q; Liu W; Huang Y; Yu P; Li Y; Ding H; Fang B
Front Pharmacol; 2017; 8():392. PubMed ID: 28701951
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of tulathromycin following subcutaneous administration in meat goats.
Young G; Smith GW; Leavens TL; Wetzlich SE; Baynes RE; Mason SE; Riviere JE; Tell LA
Res Vet Sci; 2011 Jun; 90(3):477-9. PubMed ID: 20638089
[TBL] [Abstract][Full Text] [Related]
12. In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis.
Xiao X; Sun J; Chen Y; Huang RJ; Huang T; Qiao GG; Zhou YF; Liu YH
BMC Vet Res; 2015 Feb; 11():33. PubMed ID: 25889187
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of tulathromycin injectable solution for the treatment of naturally occurring Swine respiratory disease.
Nutsch RG; Hart FJ; Rooney KA; Weigel DJ; Kilgore WR; Skogerboe TL
Vet Ther; 2005; 6(2):214-24. PubMed ID: 16094568
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial effect of Blumea balsamifera DC. essential oil against Haemophilus parasuis.
He C; Yang P; Wang L; Jiang X; Zhang W; Liang X; Yin L; Yin Z; Geng Y; Zhong Z; Song X; Zou Y; Li L; Lv C
Arch Microbiol; 2020 Nov; 202(9):2499-2508. PubMed ID: 32638056
[TBL] [Abstract][Full Text] [Related]
15. Standard PK/PD concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calf.
Toutain PL; Potter T; Pelligand L; Lacroix M; Illambas J; Lees P
J Vet Pharmacol Ther; 2017 Jan; 40(1):16-27. PubMed ID: 27501187
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Haemophilus parasuis by berberine and proteomic studies of its mechanism of action.
Jia Y; Hao C; Yang Q; Zhang W; Li G; Liu S; Hua X
Res Vet Sci; 2021 Sep; 138():62-68. PubMed ID: 34111715
[TBL] [Abstract][Full Text] [Related]
17. The influence of Actinobacillus pleuropneumoniae infection on tulathromycin pharmacokinetics and lung tissue disposition in pigs.
Gajda A; Bladek T; Jablonski A; Posyniak A
J Vet Pharmacol Ther; 2016 Apr; 39(2):176-82. PubMed ID: 26270490
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility of Haemophilus parasuis isolates from Germany by use of a proposed standard method for harmonized testing.
Brogden S; Pavlović A; Tegeler R; Kaspar H; De Vaan N; Kehrenberg C
Vet Microbiol; 2018 Apr; 217():32-35. PubMed ID: 29615253
[TBL] [Abstract][Full Text] [Related]
19. Comparison of PK/PD Targets and Cutoff Values for Danofloxacin Against
Zhou YF; Sun Z; Wang RL; Li JG; Niu CY; Li XA; Feng YY; Sun J; Liu YH; Liao XP
Front Vet Sci; 2022; 9():811967. PubMed ID: 35187143
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic Evaluation and PK/PD-Based Dose Prediction of Tulathromycin: A Potential New Indication for
Zhou YF; Peng HM; Bu MX; Liu YH; Sun J; Liao XP
Front Pharmacol; 2017; 8():684. PubMed ID: 29033841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
